Brainstorm cell therapeutics presents new analyses from nurown's phase 3 als trial at the 21st annual neals meeting

New post-hoc analyses that account for alsfrs-r floor effects add to the robust body of evidence supporting a clinically meaningful treatment effect with nurown® in als new york , nov. 7, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of a poster with new analyses from nurown's placebo-controlled phase 3 amyotrophic lateral sclerosis (als) trial that account for limitations in the revised als functional rating scale (alsfrs-r) and provide evidence of a clinically meaningful treatment effect. the poster, titled, 'further analysis of nurown phase 3 data based on baseline alsfrs-r status clarifies treatment outcomes' was presented at the 21st annual neals meeting, taking place in clearwater beach, fl and virtually.
BCLI Ratings Summary
BCLI Quant Ranking